CD200 Receptor Monoclonal Antibody (OX108), Functional Grade, eBioscience™, Invitrogen™

Description

• Description: The monoclonal antibody OX108 recognizes human CD200R also known as OX2
• CD200R is an inhibitory receptor with a similar structure as its ligand, CD200, yet lacks an ITIM domain typically found in inhibitory receptors
• Instead the CD200R cytoplasmic domain contains a novel phosphotyrosine binding domain, NPXY, which after binding SHIP inhibits ERK, JNK and MAPK p38 pathways
• In activated macrophages signaling results in inhibition of TNFalpha secretion
• Isoforms of CD200R have been identified and are thought to play a major role in differentiation, especially in regards to tolerogenic DCs
• Expression is restricted to hematopoietic cells: myeloid cells (monocytes, macrophages, DCs, neutrophils, mast cells and basophils) and a subset of T lymphocytes as well as langerhans (LC) cells and dendritic epidermal T cells
• The epitope of OX108 is thought to be near the binding site of CD200
• Applications Reported: This OX108 antibody has been reported for use in flow cytometric analysis and functional assays
• Applications Tested: This OX108 antibody has been tested by flow cytometric analysis of normal human peripheral blood cells
• This can be used at less than or equal to 0.5 μg per test
• A test is defined as the amount (μg) of antibody that will stain a cell sample in a final volume of 100 μL
• Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test
• CD200R (OX2R) is a receptor for the OX-2 membrane glycoprotein, and both the receptor and substrate are cell surface glycoproteins containing two immunoglobulin-like domains
• CD200R is restricted to the surfaces of myeloid lineage cells and the receptor-substrate interaction may function as a myeloid downregulatory signal
• In mouse, CD200R is expressed primarily by peripheral blood monocytes and neutophils but also by other leucocytes including T-lymphocytes and mast cells
• Further mouse studies of a gene related to CD200R suggests that the receptor may control myeloid function in a tissue-specific manner
• Alternative splicing of CD200R results in multiple transcript variants
• Diseases associated with CD200R dysfunction include primary hypertrophic osteoarthropathy.